Literature DB >> 6734930

The antiproliferative effect of tamoxifen in breast cancer cells: mediation by the estrogen receptor.

S Bardon, F Vignon, D Derocq, H Rochefort.   

Abstract

The effects of tamoxifen (Tam) and its 4-hydroxylated metabolite (OH-Tam) on the growth of two human breast cancer cell lines ( MCF7 and BT20 ) were evaluated by fluorometric DNA assay. The effects of the antiestrogens were dependent upon their concentrations and the nature of the cells. At concentrations below 4 microM, the degree of inhibition was related to their relative affinities for the estrogen receptor and was totally reversed by estradiol in MCF7 cells. No inhibition was observed in the estrogen receptor negative cell line BT20 . This supports and extends the idea that the antiproliferative effect of Tam at these concentrations is mediated by the estrogen receptor even in the absence of measurable estradiol concentration. At concentrations greater than 4 microM, Tam was cytotoxic on MCF7 and BT20 mammary cell lines within 2 days of treatment. The cytotoxic effect was irreversible and was not prevented by occupation of the estrogen receptor with estradiol, suggesting that it was not mediated by the estrogen receptor. The cytotoxicity of the triphenylethylene drugs, however, has some specificity since it was not observed in a fibroblast rat cell line ( 49F ) or in the two mammary cell lines with similar high concentrations of estradiol and diethylstilbestrol.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6734930     DOI: 10.1016/0303-7207(84)90004-2

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  12 in total

Review 1.  Endocrine therapy of metastatic breast cancer.

Authors:  A Manni
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

2.  Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen.

Authors:  P E Budtz
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

3.  The oestrogen antagonists, tamoxifen and FC-1157a, display oestrogen like effects on human lymphocyte functions in vitro.

Authors:  T Paavonen; L C Andersson
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

4.  A new triphenylethylene compound, Fc-1157a. I. Hormonal effects.

Authors:  S Kallio; L Kangas; G Blanco; R Johansson; A Karjalainen; M Perilä; I Pippo; H Sundquist; M Södervall; R Toivola
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.

Authors:  R Poulin; Y Merand; D Poirier; C Levesque; J M Dufour; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-10       Impact factor: 4.872

6.  Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells.

Authors:  P G Gill; F Vignon; S Bardon; D Derocq; H Rochefort
Journal:  Breast Cancer Res Treat       Date:  1987-10       Impact factor: 4.872

7.  The influence of a novel cyclopropyl antiestrogen (compound 7a) on human breast cancer cells in culture.

Authors:  P T Jain; J T Pento; R A Magarian
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

8.  The effect of tamoxifen and medroxyprogesterone on giant cell formation by monocytes from patients with breast cancer.

Authors:  A M Al-Sumidaie
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

9.  Anti-proliferative effects of 1,2-diphenylethane oestrogens and anti-oestrogens on human breast cancer cells.

Authors:  R W Hartmann; T Sinchai; G Kranzfelder
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

10.  Molecular mechanisms of estrogen action in female genital tract development.

Authors:  Myles H Alderman; Hugh S Taylor
Journal:  Differentiation       Date:  2021-02-24       Impact factor: 3.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.